Intra-Cellular Therapies (NASDAQ:ITCI) Earns "Neutral" Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Intra-Cellular Therapies (NASDAQ:ITCI - Free Report) in a research note released on Wednesday,Benzinga reports. Cantor Fitzgerald currently has a $132.00 price objective on the biopharmaceutical company's stock.

Other equities research analysts have also recently issued reports about the company. Piper Sandler reiterated a "neutral" rating and set a $132.00 price target (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Needham & Company LLC reiterated a "hold" rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Finally, Baird R W cut Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 13th. Eleven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Intra-Cellular Therapies has an average rating of "Hold" and a consensus price target of $106.23.

Intra-Cellular Therapies Stock Performance

Shares of NASDAQ ITCI remained flat at $131.87 during mid-day trading on Wednesday. The firm has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies has a 1-year low of $64.09 and a 1-year high of $131.98. The firm's 50-day moving average is $129.62 and its two-hundred day moving average is $101.80.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. Equities research analysts predict that Intra-Cellular Therapies will post -0.64 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its position in Intra-Cellular Therapies by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock worth $1,878,000 after acquiring an additional 2,157 shares during the last quarter. Barclays PLC grew its holdings in shares of Intra-Cellular Therapies by 282.0% in the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock worth $2,521,000 after purchasing an additional 25,435 shares during the last quarter. Oak Ridge Investments LLC increased its stake in shares of Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock worth $1,656,000 after buying an additional 8,440 shares during the period. Principal Financial Group Inc. raised its holdings in Intra-Cellular Therapies by 3.3% during the 3rd quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company's stock valued at $43,735,000 after buying an additional 18,865 shares during the last quarter. Finally, Merit Financial Group LLC purchased a new stake in Intra-Cellular Therapies during the 4th quarter valued at $206,000. Hedge funds and other institutional investors own 92.33% of the company's stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.